Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients.

Authors

Ilana Reinhold, Isabel Cristina Ramirez-Sanchez, Pao-Yu Chen, Yee-Chun Chen, Ankush Dhariwal, Jonathan Lambourne, Samir Agrawal, Maria Bastida, Carlota Gudiol, Serge Alfandari, Alessia Di Pilla, Sofya Khostelidi, Daniel Aguilar-Zapata, Aleksandra Barac, Ana Cipriano, Sabine Ehrlich, Jan Grothe, Jorge Illarramendi, Sara Jennrich, Reham Khedr, Dario Leotta, Gustavo-Adolfo Méndez, Julia A Nacov, Miki Nagao, Guray Saydam, Stefan Schwartz, Jörg Steinmann, Kornelius Arn, David A Enoch, Daniel Föhring, Oana Joean, Philipp Koehler, Robert Krause, Johan Maertens, Francesco Marchesi, Chizaram Onyeaghala, Neil Stone, Yuri Vanbiervliet, Nathan Wolfensberger, Luise Haensel, Julia Hurraß, Jens Panse, Ertan Sal, Jannik Stemler, Daniel Sabanés Bové, Rosanne Sprute, Maricela Valerio Minero, Antonio Vena, Livio Pagano, Oliver A Cornely, Danila Seidel, FungiScope® Working Group of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM);, Fungal Infections Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG) and the ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

Published in

EClinicalMedicine. Volume 100. Pages 104194. Epub Sep 16, 2026.

Abstract

Chronic disseminated candidiasis (CDC) is a severe manifestation of invasive candidiasis predominantly affecting patients with haematological malignancies. Treatment recommendations are based on limited observational data, and the impact of widespread antifungal prophylaxis on CDC epidemiology and outcomes remains poorly characterised. We aimed to comprehensively characterise CDC and explore associations between antifungal treatment strategies and clinical outcomes.
We performed a retrospective, multinational cohort study including adults with possible, probable, or proven CDC diagnosed between 2007 and 2025 identified through the FungiScope® registry (ClinicalTrials.gov: NCT01731353) and collaborating networks in 19 countries. Diagnostic findings, treatment strategies, and outcomes were analysed over 12 months. Exploratory comparative analyses assessed the association between antifungal treatment strategies and treatment response (composite of clinical, radiological, and mycological findings) and overall survival using inverse probability of treatment weighting to account for the time-varying confounders neutropenia and corticosteroid exposure.
Of 111 patients, CDC was classified as possible in 23.4% (n = 26), probable in 50.5% (n = 56), and proven in 26.1% (n = 29) of patients. The predominant species were Candida albicans (32.4%, n = 36) and Candida tropicalis (24.3%, n = 27); no species was identified in 30.6% (n = 34). Breakthrough CDC occurred in 24.8% (27/109) of patients. PET/CT was used in 26.1% (n = 29) of patients for follow-up. Caspofungin (36.9%, 41/111) and liposomal amphotericin B (23/111; 20.7%) were the most frequently first-line agents for antifungal treatment. No statistically significant associations were detected between first-to-second-line treatment strategy, azole selection, and treatment response. Median treatment duration was 107 days (IQR 49-182), and no CDC relapse occurred after discontinuation. Corticosteroids for immune reconstitution inflammatory syndrome were used in 4.5% of patients. All-cause mortality was 33.3% (37/111), CDC-attributable mortality was 4.5% (5/111). Overall survival was higher among patients with breakthrough CDC than without (88.9% vs 58.5%; p = 0.004).
No statistically significant associations between antifungal treatment strategy and treatment response or survival were detected in this retrospective dataset. However, the comparative treatment analyses were exploratory and the study was not powered to exclude clinically meaningful differences between antifungal strategies. Median treatment duration was shorter than previously reported. Future prospective studies integrating immunological biomarkers and the use of PET/CT-guided strategies are needed to optimise individualised treatment decision-making.
This study received no dedicated external funding. FungiScope® receives unrestricted grants for registry maintenance and infrastructure from Basilea Pharmaceutica, Melinta Therapeutics LLC, Mundipharma Ltd., and Pfizer Inc, which had no role in the study design, conduct analysis, interpretation, manuscript preparation, or the decision to submit for publication.

PMID:
42774582
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.